登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Her2 >HE2-HF256

FITC-Labeled Human Her2 / ErbB2 Protein, Fc Tag

分子别名(Synonym)

ERBB2,CD340,HER-2,neu,HER2,MLN19,NEU,NGL,TKR1

表达区间及表达系统(Source)

FITC-Labeled Human Her2 Protein, Fc Tag (HE2-HF256) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).

Predicted N-terminus: Thr 23

Request for sequence

蛋白结构(Molecular Characterization)

Her2 Structure

This protein carries a human IgG1 Fc tag at the C-terminus

The protein has a calculated MW of 96.0 kDa. The protein migrates as 115-140 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

偶联(Conjugate)

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

标记(Labeling)

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

蛋白标记度(Protein Ratio)

The FITC to protein molar ratio is 1-3.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Her2 SDS-PAGE

FITC-Labeled Human Her2 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

Her2 ELISA

Immobilized Trastuzumab at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human Her2 Protein, Fc Tag (Cat. No. HE2-HF256) with a linear range of 0.02-1.25 μg/mL (QC tested).

Protocol

 
评论(3)
  1. 158XXXXXXX1
  2. 4人赞
  3. 在实验中进行了方法构建,结果显示,这一抗原稳定性好,并且在实验过程中重复性好,可反复使用,使实验的成功率大大增加,项目进展顺利。
  4. 2022-6-15
  1. 187XXXXXXX3
  2. 0人赞
  3. 货期周期短,购买后快速发货,很快就送到,立即用来做PD1的ELISA实验检测的抗原,得到的数据重复性好,结果一致性强,不太容易出现偏差,而且贵公司还有抗原试用装,超级给力,强力推荐该产品
  4. 2022-10-19
  1. 134XXXXXXX1
  2. 0人赞
  3. 我们在实验中进行方法构建,实验的结果非常好,结果表明,这一抗原稳定性好,而且反复使用的重复性也好,大大增加了实验的成功率。
  4. 2022-1-25
 
ACRO质量管理体系
 
 

背景(Background)

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

 

前沿进展

HER2-targeted star polymer conjugates for improved tumor distribution and efficacy
Sonzini, England, Kapustin et al
J Control Release (2025)
Abstract: Actively targeted nanoparticle systems have the potential to improve delivery to tumors over untargeted systems however the design rules to achieve this have not been fully elucidated. A HER2-targeted polymer drug delivery system composed of a 32-arm star polymer (SD) conjugated with the TOP1 inhibitor molecule SN-38, with a trastuzumab antigen binding fragment (HER2-Fab), has been used to target cancer cells overexpressing this receptor. The HER2-Fab was attached to the SD at two different densities (average of 1 or 3 Fabs per star polymer) and compared to the native star polymer without Fab. In vitro experimentation showed that both the targeted star polymers (HER2-SDs) had better binding and uptake in HER2-positive cell lines (SK-BR3 and HEK293) compared to the non-targeted SD. In vivo biodistribution studies showed enhanced accumulation of HER2-targeted SDs in tumors, but not normal tissues, particularly at the later (96 h post-dose) timepoint. The HER2-SDs demonstrated increased localization with tumor cells rather than in stromal regions, greater penetration into the tumor core and a more homogenous distribution in the tumor section than the untargeted SD. The targeted star polymer conjugated to SN-38 was tested for anti-tumor activity in a HER2-positive gastric cancer xenograft in mice and showed significantly greater efficacy compared to untargeted SDs.Copyright © 2025. Published by Elsevier B.V.
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer
Berg, Ahlborn, Jensen et al
Neoplasia (2025) 63, 101162
Abstract: Among women with primary metastatic breast cancer (pMBC), around 5 % of women with primary invasive breast cancer, high-risk mutations associated with disease progression and poor prognosis is shown. The heterogeneity and clinical implications of these genomic alterations remains to be fully elucidated. We performed comprehensive gene mapping on 211 tumors of women diagnosed with pMBC at Rigshospitalet 2014-2021. After DNA purification 203 tumor samples were eligible for analysis. Median age in our cohort was 69 years, 68 % were ER-positive/HER2-negative, 23 % HER2-positive and 9 % triple-negative. A high tumor mutational burden (TMB), shown in 10 %, was in univariable analysis associated with a poor prognosis and a median overall survival of 5.3 months (95 % CI, 2.5-51.3) but no significant association after adjusting for subtype and age. 65 % of tumors had an actionable biomarker, including a PIK3CA mutation in 39 %. TP53 mutations were found in 33 % of tumors and were associated with an increased risk of death (adjusted HR: 1.60, 95 % CI; 1.07-2.40). We have found that for women with pMBC, the disease is driven by several targetable genetic mutations across subtypes, however our results suggest a reduced prognostic value of TMB for this complex patient group. Taken together, our findings substantiate the value of early genomic profiling to actively identify women that may be eligible for a more individualized treatment scheme.Copyright © 2025. Published by Elsevier Inc.
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Sahin, Rizzo, Guven et al
Cancer Treat Rev (2025) 135, 102924
Abstract: The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard first-line treatment for hormone receptor-positive (HR + ) and HER2-negative metastatic breast cancer (mBC). Despite their efficacy, resistance inevitably develops, necessitating alternative therapeutic strategies post-progression. This review explores current and emerging treatment options following progression on CDK4/6i, focusing on endocrine therapies, targeted therapies, combination approaches, and the continued use of CDK4/6i. Endocrine therapies, including fulvestrant and novel oral selective estrogen receptor degraders (SERDs) like elacestrant, show promise, especially in patients with ESR1 mutations. Targeted therapies such as PI3K/AKT/mTOR inhibitors, exemplified by alpelisib and capivasertib, offer potential by addressing downstream signaling pathways involved in resistance. Additionally, FGFR inhibitors like erdafitinib are under investigation for their role in overcoming specific resistance mechanisms. Combination strategies involving CDK4/6 inhibitors with immune checkpoint inhibitors or other targeted agents are also being explored, with early trials suggesting possible synergistic effects, although further validation is required. Continuation of CDK4/6 inhibitors beyond progression has shown potential benefits in selected patients, but the data are heterogeneous, and further studies are needed to clarify their role. While chemotherapy remains a standard option for patients who progress on these treatments, the goal is to delay its use through the effective utilization of endocrine and targeted therapies. Understanding resistance mechanisms and tailoring treatment to individual patient profiles is crucial for optimizing outcomes. Ongoing clinical trials are expected to provide deeper insights, guiding the development of more effective post-progression therapeutic strategies. This evolving landscape highlights the need for continuous research and individualized patient care to improve survival and quality of life in HR + mBC patients.Copyright © 2025 Elsevier Ltd. All rights reserved.
Construction and validation of a novel nomogram for prediction of lymph node metastasis in HER2-positive breast cancer: based on the optimal number of examined lymph nodes for accurate nodal staging
Sun, Zhang, Yang et al
BMC Womens Health (2025) 25 (1), 132
Abstract: This study aimed to construct and validate a novel nomogram for prediction of lymph node metastasis in HER2-positive breast cancer based on the optimal number of examined lymph nodes (ELNs) for accurate nodal staging.We included 4,040 patients diagnosed with HER2-positive breast cancer from the SEER database, randomly allocating them into training and validation cohorts in a 7:3 ratio. The optimal number of ELNs was identified via piecewise linear regression. The association of ELNs count with nodal migration was evaluated through Logistic Regression (LR) analysis and Random Forest (RF). The nomogram was constructed, and its' performance was evaluated by the receiver operating characteristic curves, calibration curve and Decision curve analysis curves.The optimal number of ELNs was 13. LR and RF identified the optimal number of ELNs, radiotherapy status, chemotherapy status, T stage, and grade as independent predictive variables for node metastasis, which were used in the nomogram's construction. And the area under the curve values for the nomogram were 0.829 (95% confidence interval (CI): 0.813-0.845) and 0.833 (95% CI:0.808-0.858) in the training and test split respectively, surpassing those of the optimal number of ELNs (0.649, 95% CI: 0.631-0.667 and 0.676, 95% CI:0.648-0.704). Calibration plots exhibited low Brier scores (0.150 for training split, 0.145 for test split).This study developed a novel nomogram that integrates the optimal number of ELNs with other independent risk factors, facilitating individualized prediction of lymph node metastasis in patients with HER2-positive breast cancer.© 2025. The Author(s).
Showing 1-4 of 46184 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Her2靶点信息
英文全称:Receptor protein-tyrosine kinase erbB-2
中文全称:受体蛋白酪氨酸激酶 erbB-2
种类:Homo sapiens
上市药物数量:39详情
临床药物数量:201详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定